Major depressive disorder is one of the most common and serious mental health conditions in the world. It affects how people think, feel, and function in everyday life.
Many individuals with depression struggle with persistent sadness, loss of interest in activities, fatigue, sleep problems, and feelings of hopelessness.
Although medications and therapy help many people, a large number of patients do not respond well to current treatments or experience unwanted side effects such as weight gain, sexual problems, or sleep disturbances. Because of this, scientists have been searching for faster and more effective treatment options.
A recent clinical trial has explored a new approach using a psychedelic drug called dimethyltryptamine, or DMT. Psychedelic drugs affect perception, mood, and thinking, and some have shown potential for treating mental health conditions when used under medical supervision.
In the study, researchers tested whether a single dose of DMT, combined with psychological support from trained therapists, could quickly reduce symptoms of depression.
The trial involved 34 adults diagnosed with major depressive disorder. Participants were randomly divided into two groups. In the first stage of the study, one group received DMT while the other received a placebo, which contained no active drug.
Neither the participants nor the researchers knew who received which treatment during this phase. Two weeks later, the study entered a second stage in which all participants were offered DMT treatment along with therapist support, and both patients and researchers knew the treatment being given.
Unlike some other psychedelic substances, DMT acts very quickly and its effects last for a much shorter time. When given through an intravenous infusion, the psychedelic experience typically lasts about 30 minutes.
In comparison, treatments using psilocybin, a compound found in certain mushrooms, can last several hours. The short duration of DMT could make therapy sessions easier to manage and more accessible in clinical settings.
After two weeks, participants who had received DMT during the first stage showed a greater improvement in their depression symptoms compared to those who received the placebo.
Researchers measured symptoms using a standard clinical rating scale commonly used in mental health research. Improvements were noticeable as early as one week after treatment and continued over the following weeks.
In the second stage of the trial, the benefits of DMT appeared to last for up to three months. Interestingly, there was no clear difference between participants who received one dose and those who received two doses.
Most side effects were mild or moderate, including temporary nausea, anxiety, or discomfort at the infusion site. No serious treatment-related complications were reported during the study.
The findings suggest that DMT, combined with psychological support, could become a fast-acting treatment option for depression.
However, the researchers emphasize that the study involved a small number of participants and that larger trials are needed to confirm the results. Scientists also need to understand how long the benefits truly last and how this treatment compares with existing therapies.
When reviewing these findings, it is important to note that psychedelic therapy must be conducted in a safe medical setting with trained professionals. These substances can produce powerful psychological effects and are not suitable for unsupervised use.
The study does not suggest that people should self-medicate, but rather that carefully controlled clinical use may offer new hope for those who have not benefited from traditional treatments.
Overall, the research represents a promising step forward in the search for better depression treatments. If future studies confirm these results, fast-acting therapies like DMT could provide relief for patients who have struggled for years with limited options.
While more evidence is needed, the study highlights how new approaches to mental health care could transform treatment in the coming years.
If you care about health, please read studies that scientists find a core feature of depression and this metal in the brain strongly linked to depression.
For more health information, please see recent studies about drug for mental health that may harm the brain, and results showing this therapy more effective than ketamine in treating severe depression.
Copyright © 2026 Knowridge Science Report. All rights reserved.
